AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 09:05:08 17/06/2024 pm IST 5-day change 1st Jan Change
12,428 GBX -0.66% Intraday chart for AstraZeneca PLC -1.37% +17.25%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
European Equities Close Mixed in Monday Trading; UBS Sued by Russian-Uzbek Billionaire Usmanov MT
Global markets live: AstraZeneca, Apple, Meta, Microsoft, Cisco... Our Logo
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer MT
AstraZeneca: positive phase 3 results in lymphoma CF
AstraZeneca's Blood Cancer Combination Therapy Meets Primary Goal in Late-Stage Study MT
London stocks rebound ahead of key Economic data Our Logo
Astra's Imfinzi plus chemo approved for cancer form in US AN
AstraZeneca: Imfinzi approved in endometrial cancer CF
Astra gets US drug approval; Ascential trades in line AN
AstraZeneca Gains US FDA Approval for Endometrial Cancer Treatment MT
UK Stocks-Factors to watch on June 17 RE
AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer DJ
AstraZeneca gets positive cancer test results for Calquence AN
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer RE
AstraZeneca's Calquence Combo Extends Progression-free Survival in Mantle Cell Lymphoma Study MT
AstraZeneca Announces CALQUENCE (Acalabrutinib) Plus Chemoimmunotherapy Reduced the Risk of Disease Progression or Death by 27% Vs. Standard of Care in Patients with Untreated Mantle Cell Lymphoma in Echo Phase III Trial CI
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading MT
Tesla, Inc. : Musk moves a step closer to the $56 billion prize and the transfer of Tesla's headquarters to Texas Our Logo
AstraZeneca: Farxiga approved for diabetes as of age 10 CF
AstraZeneca's Type-2 Diabetes Drug Wins Pediatric Approval in US MT
US Food and Drug Administration Approves AstraZeneca?s FARXIGA in the US for the Treatment of Pediatric Type-2 Diabetes CI
AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S. DJ
AstraZeneca Gets FDA Approval for Pediatric Type-2 Diabetes Control Drug MT
AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes AN
European Equities Close Lower in Monday Trading Following Far Right Gains in EU Elections MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6 USD
Average target price
174.4 USD
Spread / Average Target
+9.95%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India